Jieshi Medical Secures Series B Funding to Advance Domestic Substitution in Ophthalmic High-Value Consumables with Perfluoropropane Gas and Next-Gen Heavy Liquid
VCBeat learned at the first time,Shanghai Jieshi Medical Technology Co., Ltd. (referred to as "Jieshi Medical")Successfully completed byJunsheng CapitalLead investment,Xingliang InvestmentB-round financing. The funds will be used to accelerate the commercialization of core products, develop new products, and expand the market.
In China's ophthalmic medical device field, especially in high-value consumables, there has been a long-term reliance on imports. For example, in complex vitreoretinal surgery,"Choking" surgical critical materials such as intraocular filling gas and heavy water (liquid instruments) for ophthalmic surgery have been localized in China.The degree is almost zero.Imported products are not only expensive but also have problems such as unstable supply, which not only restricts the popularization of retinal surgery but also seriously affects the surgical treatment of patients with fundus diseases who need timely vision rescue.
Shanghai Jieshi Medical Technology Co., Ltd. was established in January 2013 at the Zhangjiang Medical Device Industry Base. The company is committed to the research, development, and production of systematic solutions in the two major fields of fundus diseases and visual reconstruction, and has now preliminarily formedProduct Matrix——JetVision® Perfluoropropane Gas for Ophthalmology, HeavyWater® Perfluorooctane for Ophthalmic Surgery, Disposable Ophthalmic Puncture System, Silicone Oil Injection and Aspiration Kit, Ophthalmic Irrigation (Injection and Aspiration) NeedleSeveral products have been the first to gain approval and come to market in China. Products such as silicone oil for ophthalmic surgery, disposable vitrectomy probes/laser fibers/illumination fibers, and artificial corneal endothelium are currently in the research and development process.
Among them,Shanghai Jieshi Medical Technology Co., Ltd.'s self-developed perfluoropropane gas for ophthalmic use (trade name: Jieshi®) obtained the NMPA Class III certificate this February, becoming the first domestically produced disposable long-acting ophthalmic filling gas to be approved in China.This product is specifically designed for vitreoretinal surgery, used for intraocular filling treatment, and can effectively promote the repositioning and healing of detached retinas.
Jieshi® Perfluoropropane Gas for Ophthalmic Use has C3F8 as its main component. It is colorless, transparent, and chemically stable, and can be used within the vitreous cavity. After injection, it is gradually expelled through the blood and respiratory system, eliminating the need for a second surgery to remove it. With 30mL independent and binary protective packaging, along with a disposable design, it directly addresses the pain points of high prices of imported products, repeated use, and the risk of nosocomial infections. Moreover, with a high purity of 99%, it sets a new industry standard, completely ending the long-standing dilemma in China where there was no domestically produced long-acting gas available for retinal surgeries, and where treatment delays occurred due to shortages of imported ophthalmic gases.
Jieshi® Perfluoropropane Gas for Ophthalmic Use (China Medical Device Registration No. 20253160327)
In addition,Shanghai Jieshi Medical Technology Co., Ltd. developed perfluorooctane for ophthalmic surgery (brand name: Heavy Water®), which is also the only second-generation heavy water produced in China.Compared with the first-generation heavy water (mainly composed of perfluorodecalin, purity ≥ 95%), Jieshi Heavy Water® is primarily composed of perfluorooctane. It has stable chemical properties and is highly inert, making it less likely to trigger biological or enzymatic reactions in the body. It boasts higher purity (purity ≥ 99.98%), a lower relative density, which exerts less mechanical pressure on the retina at the same volume, thus enhancing safety. With a higher relative vapor pressure (high vapor pressure at 35°C: 6.0-8.0 kPa), it is easier to volatilize post-surgery and less likely to leave residues. Its refractive index (1.26) is close to that of water (1.33), providing better color restoration for the fundus, making it not only easier to identify but also maintaining good refractive media during surgery. Additionally, it has a high boiling point (102-106°C), reducing the likelihood of vaporization during intraocular photocoagulation.
Heavy Water® Perfluorooctane for Ophthalmic Surgery (NMPA Approval No. 20203160015)
For this round of financing,Founder of Shanghai Jieshi Medical Technology Co., Ltd., Zhao HongbingExpress: Our heartfelt gratitude to all investors for their trust and support in Jieshi Medical amidst the current environment! This high expectation bestows upon us a dual mission—to work diligently while striving ambitiously for breakthroughs. The innovation and self-reliance of China's ophthalmic medical device industry require solidarity from all industry peers. Let us join hands to outline an independent blueprint and embark on a bright future together! The road ahead is long and arduous, but walking it will lead us to our destination; persistent action will eventually bring the dawn. For more brightness, we persevere without fail!
Dr. Guo Yunlong, Founding Partner of Junsheng CapitalWith the trend of aging and economic development, the demand for diagnosis and treatment of ophthalmic diseases continues to increase. Shanghai Jieshi Medical Technology Co., Ltd. is a high-quality enterprise in China's ophthalmic medical device field. Through independent innovation and R&D, it has differentially laid out products in two major fields: fundus diseases and visual reconstruction. Multiple self-developed products, such as perfluoropropane gas for ophthalmology and perfluorooctane heavy water for ophthalmology, have broken the gap in domestically produced products. Additionally, several innovative products are expected to become the first of their kind in China. The Jieshi Medical team has extensive R&D and operational experience in the ophthalmic device field. Guided by clinical pain points, they focus on product development with the aim of benefiting a wide range of patients with ophthalmic diseases through independent innovation.
Yang Shixian, Managing Partner of Star CapitalEyes are the windows to the human soul! Currently, the localization rate of ophthalmic medical devices in China is significantly behind other medical specialties. However, with the emergence of innovative, forward-thinking, and hardworking domestic ophthalmic device R&D and manufacturing companies like Shanghai Jieshi Medical Technology Co., Ltd., the future of ophthalmology in China will undoubtedly be brighter! Shanghai Jieshi Medical Technology Co., Ltd. has initially formed a product portfolio for vitreoretinal surgical consumables, with several products being the first to fill domestic gaps or reach the market. It must leverage its strengths, excel in market sales, optimize professional services, and strengthen solutions. The prospects are bound to be brilliant! Wishing Shanghai Jieshi Medical Technology Co., Ltd. continued success and further achievements!
About Junsheng Capital
Junsheng Capital is a professional equity investment management institution, focusing on the healthcare, new materials, and intelligent manufacturing sectors. In the healthcare sector, Junsheng Capital has invested in high-quality enterprises such as Bioridge Biotechnology, Yafei Biotech, Meivida Medical, and Guizhou Sanli (603439), targeting market pain points and guided by the needs of patients and doctors to support the development of China's healthcare industry.
About Star Capital
Xingliang Investment is a private equity fund management institution focused on early-stage, mid-stage, and growth-stage project investments. The core members of the team come from government, industry, and financial investment institutions, with decades of deep cultivation in related fields. Xingliang Investment accurately grasps the major trends in industry development, focusing on technology projects, with particular attention to industries such as biomedicine, advanced manufacturing, and new materials. They carefully select potential leading enterprises and seize the right investment opportunities. Currently, the team is responsible for managing and operating multiple equity investment funds, has invested in over 50 projects, and has helped several projects successfully go public.